LONDON (Thomson Financial) - AstraZeneca Plc has announced along with
partner Bristol-Myers Squibb Company that it has submitted a New Drug
Application in the US and a Marketing Authorisation Application in the EU for
its diabetes drug Onglyza, based on saxagliptin.
The submission is significant for the company as Onglyza is seen as one of
its potential new blockbusters.
The submission is slightly behind schedule as the Anglo/Swedish company has
said that it would file by the middle of this year.
ben.deighton@thomsonreuters.com
bsd
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|